Myonexus Therapeutics Receives FDA Rare Pediatric Drug Designation for Pioneering Treatment of Limb Girdle Muscular Dystrophy Type 2E | Business Wire

Myonexus Therapeutics Receives FDA Rare Pediatric Drug Designation for Pioneering Treatment of Limb Girdle Muscular Dystrophy Type 2E | Business Wire: Myonexus Therapeutics receives FDA Rare Pediatric Drug Designation for pioneering gene therapy treatment of limb girdle muscular dystrophy type 2E.